LDLR and hyperlipidemia: It is postulated that apoE4 promotes hyperlipidemia because its preference for triglyceride-rich lipoproteins may accelerate their plasma clearance, leading to down-regulation of the LDL receptor and a corresponding increase in plasma LDL and atherosclerosis risk [17].